title: Sorafenib: 10 years after the first pivotal trial.
abstract: Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of cancers. It is currently approved for the treatment of patients with hepatocellular carcinoma, advanced renal cell carcinoma or progressive, locally advanced or metastatic differentiated thyroid carcinoma. In this review, we present a number of studies that investigated the efficacy and safety of sorafenib in these settings. We also discuss the perspectives on the use of this molecule, including the role of sorafenib as comparator for the development of new drugs, the combination of sorafenib with additional therapies (such as transarterial chemoembolization for hepatocellular carcinoma) and the use of this treatment in several other advanced refractory solid tumors.
authors.affiliation: Medical Oncology Unit, 'Mons. R Dimiccoli' Hospital, Viale Ippocrate, 15, 76121 Barletta, Asl BAT, Italy.
authors.forename: Gennaro
authors.initials: G
authors.lastname: Gadaleta-Caldarola
authors.affiliation: Medical Oncology Unit, 'S Francesco di Paola' Hospital, Via Promintesta, 87027 Paola, ASP, Cosenza, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Infusino
authors.affiliation: Laboratory of Clinical and Experimental Pathology - National Cancer Institute 'Giovanni Paolo II', Viale Orazio Flacco 65, 70124, Bari, Italy.
authors.forename: Rosa
authors.initials: R
authors.lastname: Divella
authors.affiliation: Department of Internal Medicine & Clinical Specialties, University of Rome 'La Sapienza', Policlinico Umberto I, Viale del Policlinico, 155, 00161 Roma, Italy.
authors.forename: Emanuela
authors.initials: E
authors.lastname: Ferraro
authors.affiliation: Interdisciplinary Department of Medicine, University of Bari School of Medicine, Piazza G Cesare, 11,70124 Bari, Italy, National Institute for Digestive Diseases, IRCCS 'Saverio De Bellis', Via Turi 27, 70013, Castellana Grotte, Bari, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Mazzocca
authors.affiliation: Psychoncology Unit, DSM Cosenza, ASP, Cosenza, Italy.
authors.forename: Ferruccio
authors.initials: F
authors.lastname: De Rose
authors.affiliation: Medical Oncology Unit, 'S Francesco di Paola' Hospital, Via Promintesta, 87027 Paola, ASP, Cosenza, Italy.
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Filippelli
authors.affiliation: Laboratory of Clinical and Experimental Pathology - National Cancer Institute 'Giovanni Paolo II', Viale Orazio Flacco 65, 70124, Bari, Italy.
authors.forename: Ines
authors.initials: I
authors.lastname: Abbate
authors.affiliation: Medical Oncology Unit, 'Mons. R Dimiccoli' Hospital, Viale Ippocrate, 15, 76121 Barletta, Asl BAT, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Brandi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
keywords: GIST; HCC; NSCLC; breast cancer; mRCC; melanoma; quality of life; sarcoma; sorafenib; thyroid cancer